Amphastar Pharmaceuticals, Inc.
AMPH
$27.23
-$0.36-1.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 723.76M | 720.74M | 725.71M | 712.81M | 681.49M |
| Total Other Revenue | -455.00K | 1.94M | 4.95M | 19.15M | 42.06M |
| Total Revenue | 723.31M | 722.68M | 730.66M | 731.97M | 723.55M |
| Cost of Revenue | 366.27M | 362.35M | 361.65M | 358.11M | 340.20M |
| Gross Profit | 357.04M | 360.33M | 369.01M | 373.86M | 383.35M |
| SG&A Expenses | 126.42M | 99.27M | 97.34M | 94.52M | 92.90M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 573.36M | 541.01M | 535.96M | 526.55M | 509.29M |
| Operating Income | 149.94M | 181.67M | 194.70M | 205.42M | 214.26M |
| Income Before Tax | 135.67M | 161.84M | 172.75M | 189.19M | 186.07M |
| Income Tax Expenses | 24.04M | 27.13M | 31.12M | 29.67M | 28.35M |
| Earnings from Continuing Operations | 111.63 | 134.71 | 141.63 | 159.52 | 157.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.63M | 134.71M | 141.63M | 159.52M | 157.72M |
| EBIT | 149.94M | 181.67M | 194.70M | 205.42M | 214.26M |
| EBITDA | 205.73M | 236.73M | 248.30M | 258.39M | 266.61M |
| EPS Basic | 2.36 | 2.81 | 2.93 | 3.29 | 3.26 |
| Normalized Basic EPS | 1.79 | 2.11 | 2.23 | 2.44 | 2.40 |
| EPS Diluted | 2.26 | 2.67 | 2.76 | 3.06 | 3.01 |
| Normalized Diluted EPS | 1.71 | 2.01 | 2.10 | 2.27 | 2.22 |
| Average Basic Shares Outstanding | 189.04M | 191.19M | 193.14M | 193.72M | 193.70M |
| Average Diluted Shares Outstanding | 197.01M | 201.19M | 205.11M | 208.23M | 209.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |